AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01897948 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Milk-based beverage without DHA
Study NCT01897948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Milk-based beverage with DHA at mid level
Study NCT01897948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Milk-based beverage with DHA at high level
Study NCT02675010 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ENDOSCOPIC GASTRIC BIOPSIES FROM ANTRUM AND BODY
Description: ENDOSCOPIC GASTRIC BIOPSIES FROM ANTRUM AND BODY
Study NCT01491997 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mind/Body Medicine Course 1
Description: The subject of the course is Mind/Body medicine. This course is learning about the mind and the body through experiences. The course will meet once every week, for a total of 8 weeks, for roughly 2 hours per class. You will be provided with a schedule of the weekly classes, which will occur on the same day every week, at the same time. Weekly sessions will be run by a teacher and will include other participants in the class. You will also be given homework assignments that are intended to reinforce what you learn in the program. The assignments will require up to 45 minutes, 6 days/week. Following the 6th class, and before the 7th class, there is a voluntary all day Saturday program. Participation in this program is optional. You are expected to continue to incorporate what you learned in the class in your daily routine after you are done with the classes.
Study NCT01491997 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mind/Body Medicine Course 2
Description: The subject of the course is Mind/Body medicine. This course is learning about the mind and the body through lectures. The course will meet once every week, for a total of 8 weeks, for roughly 2 hours per class. You will be provided with a schedule of the weekly classes, which will occur on the same day every week, at the same time. Weekly sessions will be run by a teacher and will include other participants in the class. You will also be given homework assignments that are intended to reinforce what you learn in the program. The assignments will require up to 45 minutes, 6 days/week. Following the 6th class, and before the 7th class, there is a voluntary all day Saturday program. Participation in this program is optional. You are expected to continue to incorporate what you learned in the class in your daily routine after you are done with the classes.
Study NCT00432341 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin type A
Description: 200 Units at Visit 1 (Day 1)
Study NCT00432341 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: botulinum toxin type A
Description: 500 Units at Visit 1 (Day 1)
Study NCT04383782 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Expectancy Challenge
Description: Expectancy challenge intervention (see description in study arms).
Study NCT04383782 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expectancy Challenge + Behavioral Activation
Description: Expectancy challenge + behavioral activation interventions (see description in study arms)
Study NCT04383782 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Neutral reading condition (see description in study arms).
Study NCT04819022 — intervention group
Intervention type: DEVICE
Intervention: Post-surgical
Description: These programs will cover patients submitted to surgery for a given musculoskeletal condition, including, but not limited to, shoulder tendon repair, shoulder replacement, spinal surgery, hip or knee replacement, meniscal repair, knee ligament reconstruction, undergoing physical rehabilitation programs after surgery.
Study NCT02173015 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compensatory step training
Description: The training consists of a progression of anterior or posterior treadmill belt movements applied as the subject is standing or walking. This training specifically focuses on aspects important to trip and slip recovery. Subjects will participate in up to 6 sessions in 7 to 30 days. The training intensity (magnitude of disturbance delivered) is progressive and dependent on subject performance. Subjects will be instructed to respond with single or multiple steps in order to prevent a fall. All subjects will be outfitted with a safety harness to prevent injury. Up to 72 disturbances will be delivered each session.
Study NCT01249404 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: I.M. injection on day 1 (single treatment cycle)
Study NCT01249404 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: I.M. injection on day 1 (single treatment cycle)
Study NCT01856920 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-6207 [Recombinant Saccharomyces cerevisiae-CEA (610D)]
Description: GI-6207 is a heat-killed, recombinant yeast-based vaccine engineered to express the full length human carcinoembryonic antigen (CEA), with a modified gene coding sequence to code for a single amino acid substitution (asparagine to aspartic acid) at the native protein amino acid position 610, which is designed to enhance immunogenicity. A plasmid vector containing the modified human CEA gene is used to transfect the parental yeast strain (S. cerevisiae W303 - a haploid strain with known mutations from wild-type yeast) to produce the final recombinant vaccine product.
Study NCT00528294 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: GRID radiotherapy
Description: GRID-radiotherapy followed by biological imaging guided IMRT
Study NCT02653131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dipeptidyl peptidase-4 inhibitor
Study NCT03011931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: 20 mg Simvastatin given, Blood draw, Urine collection, Celiac serology testing, DNA sampling, Dietary review
Study NCT04601389 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Omalizumab (JSC GENERIUM, the Russian Federation)
Description: 150 mg of omalizumab was subcutaneously injected once in the deltoid muscle area
Study NCT04601389 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Xolair® (Novartis Pharma AG, Switzerland)
Description: 150 mg of omalizumab was subcutaneously injected once in the deltoid muscle area
Study NCT03112759 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Cognitive behavioral therapy (CBT) uses pain coping skills as a method of managing symptoms associated with chronic pain.Cognitive behavioral therapy teaches patients to identify and modify negative thoughts and behaviors that increase pain intensity, distress, and pain-related disability
Study NCT04508504 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preop PENG block
Description: Ultrasound-guided injection of 20 mL 0.5% ropivacaine according to the method described by Giron-Arango L in 2018. A needle is inserted at the inguinal level under ultrasound guidance to pass beneath the psoas tendon on top of the iliopubic eminence where the local anesthetic is injected.
Study NCT04508504 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo block
Description: Ultrasound-guided placebo injection of 5 mL 0.9% normal saline. Using the same landmarks as for the PENG group, a needle is inserted in the inguinal region under ultrasound guidance, whereby a subcutaneous injection of 5 mL of 0.9% saline is made.
Study NCT04508504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% Injectable Solution
Description: 20 mL 0.5% ropivacaine will be injected for the preop PENG block
Study NCT04508504 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 5 mL 0.9% Normal saline will be injected for the Placebo block
Study NCT01722630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dopamine
Study NCT03027258 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth
Description: HBI participants who consent will be enrolled in this study and will have data collected from their community screening stored in a secure, web-based database. The stored data will be encrypted into a Quick Response code embedded in a smart card. A unique identification number and participant's blood group type will be on the outside of the card. There will be no names or any other identifiers. Each participating center will identify a dedicated delivery room staff that will be trained to read the contents of the card using the cell phone application as well as enter new data in the participant's profile. When a participant presents at delivery without the card, information can still be obtained from the secure, web-based database and confirmed using the participant's name, date of birth and cell phone number. This information is provided to the clinician to guide management of the infant.
Study NCT02415491 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Correlation Heart Magnetic Resonance Imaging at rest and stress with Cardiopulmonary stress test
Description: MRI of the heart, coronary arteries and pulmonary artery at rest and stress induced will be performed. Cine pictures are taken for evaluation of pulmonary perfusion.~Afterwards induced stress MRI will be performed according to standard protocol with elevation of dobutamine levels until the reach of peak HR. If applicable the procedure will be stopped) in case of e.g. arrhythmia.~Cardiopulmonary exercise stress test will be performed; patient will sit at rest on the ergometer, the subject's gas exchange will be recorded; with the pedal speed constant, the resistance will be increased from 0.5 watt/kg to 3 watt/kg over 10 minutes. Electrocardiography and heart rate will be taken continuously during and until 10 minutes afterwards. Blood pressure will be taken before, during and after the stress test. Respiratory gas exchange parameters will be taken continuously, peak oxygen uptake (VO2) determined as well as Ventilatory Efficiency.
Study NCT02967822 — intervention group
Intervention type: GENETIC
Intervention: Biological samples for patients
Description: Blood samples. Sampling of uterine tissue during surgical intervention (collection of samples for the study only if samples remain after the routine care analyses)
Study NCT02967822 — intervention group
Intervention type: GENETIC
Intervention: Biological samples for healthy relatives
Description: Blood samples.
Study NCT02069379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Women classified as insulin resistant will participate in both a placebo and a metformin treatment arm, each lasting about 16 weeks. Women will be randomized to order of treatment arms.
Study NCT02440243 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Purethal
Description: prerseasonal course of SCIT - three years
Study NCT02440243 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Purethal -placebo
Description: preseasonal course of SCIT - three years
Study NCT02480517 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Study NCT04510662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Description: Patients in this group will receive telmisartan 40 mg daily plus standard care.
Study NCT04144140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7766
Description: E7766, solution, intratumorally
Study NCT04465591 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: troponin T fragmentation test
Description: laboratory test from blood sample
Study NCT02844231 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Single-photon emission computed tomography
Study NCT02480517 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Ultrasound
Study NCT00230711 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity counseling
Study NCT03605277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asciminib
Description: 40 mg single dose
Study NCT02069379 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules prepared identically to Metformin capsules
Study NCT04051515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intradialysis exercise training
Description: Combined exercise, aerobic and resistance training, implemented by nursing staff
Study NCT04051515 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home-based exercise training
Description: Combined exercise, aerobic and resistance training, implemented independently home
Study NCT02335411 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: IV infusion
Study NCT02335411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: IV infusion
Study NCT02335411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: IV infusion
Study NCT02335411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: oral tablets
Study NCT04165174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terepril monoclonal antibody; Apatinib
Description: Terepril monoclonal antibody,240mg,ivdrip,Q3W Apatinib,250mg,po,QD
Study NCT04165174 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: 6-10Gy/F,5-8F
Study NCT03041012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Romidepsin
Description: 5mg/m2 romidepsin will be administered IV on days 10, 17, and 24 after initiating ART
Study NCT02516449 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient decision aid
Description: The patient decision aid is a 12-page A3 size color-printed booklet entitled Should I take asthma inhaled controller medication to optimize asthma control?
Study NCT04480359 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bawei Shenqi Pill
Description: 5.1g, once a day, 3month, oral
Study NCT04480359 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bawei Shenqi Pill placebo
Description: 5.1g, once a day, 3month, oral
Study NCT04480359 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meloxicam
Description: 7.5mg, once a day, 3 month, oral
Study NCT04480359 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Meloxicam
Description: 7.5mg, once a day, 3 month, oral
Study NCT00960869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA32540
Description: PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole
Study NCT00960869 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EC-Aspirin 325 mg
Description: The comparator aspirin 325 mg enteric coated tablet (PA32540 minus omeprazole)
Study NCT03240042 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nasotracheal intubation
Description: The participants either receive intubation via nasal route.
Study NCT03240042 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: orotracheal intubation
Description: The participants either receive intubation via oral route.
Study NCT03288636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danoprevir
Description: Danoprevir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23
Study NCT03288636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23
Study NCT03288636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravidasvir
Description: Ravidasvir tablet administered orally 200mg QD on day 1, 13 - 23
Study NCT03288636 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01518374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Florbetapir F 18
Description: 370 MBq (10 mCi)
Study NCT01968772 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Transdermal Magnesium Chloride
Description: Each participant will be provided with a spray bottle containing a transdermal magnesium chloride solution and asked to apply 4 sprays per each arm and each leg 2 times a day as follows: pump 4 sprays into the palm of your hand and apply to each arm and each leg 2 times a day for a total of 32 sprays daily. Rub the contents of 4 sprays on one limb and repeat for each limb coating evenly.
Study NCT04113187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol treatment
Description: 40 mg twice a day (morning and evening), per os, during three months
Study NCT04113187 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: per os, twice a day (morning and evening) during three months
Study NCT00673699 — intervention group
Intervention type: PROCEDURE
Intervention: Gastric mucosal biopsy
Description: Using upper gastrointestinal endoscopy with targeting biopsy in patients with dyspepsia
Study NCT02950727 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3 bicortical screws
Description: after mandibular bilateral sagittal split ramus osteotomy surgery is performed in the first group the osteotomy will be fixed using 3 bicortical screws
Study NCT02950727 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: adjustable plate and 2 bicortical screws
Description: after mandibular bilateral sagittal split ramus osteotomy surgery is performed in the second group the osteotomy will be fixed using adjustable plate and 2 bicortical screws
Study NCT03041012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3BNC117
Description: 30 mg/kg 3BNC117 will be administered IV on day 7 and 21 after initiating ART
Study NCT03041012 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antiretrovirals
Description: Combination antiretroviral therapy
Study NCT03041012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiretrovirals
Description: Combination antiretroviral therapy
Study NCT04037592 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active standardized iTBS-DMPFC
Description: Participants in the standardized dosage(600 pulse) of intermittent TBS(iTBS) active stimulation group will receive 3-week three-pulse 50-Hz bursts administered every 200 milliseconds (at 5 Hz) at an intensity of 80% active motor threshold (MT) to bilateral DMPF, twice a day. Bilateral side DMPFC will be targeted by MRI-neuronavigation system. Stimulation will be delivered to the DMPFC using a Magstim stimulator.
Study NCT04037592 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active high-dosage iTBS-DMPFC
Description: Participants in the standardized dosage(1800pulse) of intermittent TBS(iTBS) active stimulation group will receive 3-week three-pulse 50-Hz bursts administered every 200 milliseconds (at 5 Hz) at an intensity of 80% active motor threshold (MT) to bilateral DMPF, twice a day. Bilateral side DMPFC will be targeted by MRI-neuronavigation system. Stimulation will be delivered to the DMPFC using a Magstim stimulator.
Study NCT04037592 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham standardized iTBS-DMPFC or high-dosage iTBS-DMPFC
Description: Half of the patients in the sham group received 3-week the same standardized iTBS parameter stimulation (standardized sham-iTBS), and the other half received the same high dosage iTBS parameter stimulation using a sham coil (high dosage sham-rTMS), which also improved the blinding process
Study NCT00623844 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity
Description: activity program at kindergarten 5 \* 30 min per week plus education of parents (letters, flyers, presentations, counselling) plus activity homework for children involving also the families
Study NCT03057197 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: new caudal injection technique
Description: new caudal injection technique is applied to the Group B, which is that the needle only penetrates the sacrococcygeal ligament without being inserted into the sacral canal
Study NCT02027766 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calf muscle stretching
Study NCT00975793 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Goal Directed Therapy (EGDT)
Description: Randomised allocation of early goal-directed therapy (EGDT). EGDT involves treatment with intravenous fluids, and medications to support the blood pressure and heart following a protocol. A special catheter is inserted to monitor central blood oxygen levels and the standard treatments are given according to the blood oxygen level reading. EGDT is given for 6 hours, then the patient receives standard care.
Study NCT03580746 — intervention group
Intervention type: PROCEDURE
Intervention: Taping and posteromedial release
Study NCT03580746 — intervention group
Intervention type: PROCEDURE
Intervention: Ponseti
Study NCT03647995 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiolife by Green Made (Pharma M)
Description: A box containing 30 capsules of a dietary supplement containing 25 Bn CFU (detailed in previous sections)
Study NCT03647995 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A box containing 30 capsules containing an inactive substance with 0 Bn CFU.
Study NCT03143270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug Eluting Bead Transarterial Chemoembolization
Description: Hepatic embolization will occur on Day 0 of the study for all cohorts. On the day of the procedure, baseline angiography including celiac and superior mesenteric angiography will be performed to delineate arterial anatomy and blood supply to the tumor. After the entire dose has been used, the embolized vessels will be re-catheterized and embolized to stasis with Bead Block beginning with 100-300 micron spheres and using a maximum of 10 cc of any given size per vessel before moving to the next size microsphere.